ライフサイエンスコーパス: hyperlipidemia

1 confidence interval, 1.05-1.85 per decade of hyperlipidemia).

2 y complications (diabetes, hypertension, and hyperlipidemia).

3 c abnormalities (diabetes, hypertension, and hyperlipidemia).

4 abetes mellitus, ischaemic heart disease and hyperlipidemia.

5 ght constitute a novel approach for treating hyperlipidemia.

6 in increased hepatic de novo lipogenesis and hyperlipidemia.

7 lerate thrombosis in mice in the settings of hyperlipidemia.

8 or the treatment of hypercholesterolemia and hyperlipidemia.

9 HE is not significantly associated with hyperlipidemia.

10 osis, and atherosclerosis in the settings of hyperlipidemia.

11 patients with chronic periodontitis (CP) and hyperlipidemia.

12 rowth of breast cancer using mouse models of hyperlipidemia.

13 ecreased atherosclerotic plaque formation in hyperlipidemia.

14 1.64; 95% CI, 1.02-2.68) but not obesity or hyperlipidemia.

15 ditions, such as diabetes, hypertension, and hyperlipidemia.

16 cluding hyperglycemia, hyperinsulinemia, and hyperlipidemia.

17 tolerance, weight gain, hepatosteatosis, and hyperlipidemia.

18 Zealand White (NZW) rabbits on diet-induced hyperlipidemia.

19 animal models of acute and high-fat-induced hyperlipidemia.

20 tor class B type 1 may account for alcoholic hyperlipidemia.

21 CCD36 and accelerated thrombosis observed in hyperlipidemia.

22 M2 patients and patients with statin-treated hyperlipidemia.

23 tes control and remission, hypertension, and hyperlipidemia.

24 ses the polyol pathway, AGEs production, and hyperlipidemia.

25 optosis of vascular smooth muscle cells, and hyperlipidemia.

26 n type 9 (PCSK9) has been developed to treat hyperlipidemia.

27 s a chronic inflammatory disease promoted by hyperlipidemia.

28 (n = 121), ascertained for familial combined hyperlipidemia.

29 egarding periodontal status of patients with hyperlipidemia.

30 thus a promising target for the treatment of hyperlipidemia.

31 velopment of obesity, insulin resistance and hyperlipidemia.

32 de transfer protein (MTP), can contribute to hyperlipidemia.

33 loss (38% versus 26%) after the reversal of hyperlipidemia.

34 syndrome with proteinuria, weight gain, and hyperlipidemia.

35 s were found for patients without history of hyperlipidemia.

36 D) for 28 weeks, resulting in steatosis with hyperlipidemia.

37 th that of brain CD36 to stroke pathology in hyperlipidemia.

38 were found for duration of hypertension and hyperlipidemia.

39 sened metrics of diabetes, hypertension, and hyperlipidemia.

40 olic disorders such as obesity, diabetes and hyperlipidemia.

41 ed thrombosis specifically in the setting of hyperlipidemia.

42 ies that have been extensively used to treat hyperlipidemia.

43 emia, kidney donor risk index, and recipient hyperlipidemia.

44 valent HRP prevalence as older patients with hyperlipidemia.

45 f lipid droplets in hepatocytes and systemic hyperlipidemia.

46 on of remnant lipoproteins, and postprandial hyperlipidemia.

47 responding lipid levels and risk of incident hyperlipidemia.

48 isk factors for lipids increase and incident hyperlipidemia.

49 s of treatment of hypertension (0-2 points), hyperlipidemia (0-2 points), and atrial fibrillation (0-

50 r hypertension, 0.97 (95% CI: 0.88-1.08) for hyperlipidemia, 1.01 (95% CI: 0.89-1.15) for diabetes me

51 .6%]; hypertension, 3.2% [CI, 2.2% to 4.2%]; hyperlipidemia, 1.5% [CI, 0.6% to 2.5%]).

52 smoking, diabetes mellitus, hypertension, or hyperlipidemia), 1036 subjects had 1 to 2 RF, and 1253 h

53 hotic; hazard ratio=1.63, 95% CI=0.98-2.70), hyperlipidemia (12.9% for clozapine vs. 8.5% for standar

54 We also found high prevalences of hyperlipidemia (24.5%), hypertension (21.9%), and gastro

55 ion (31.4%, 39.3%, and 76.2%, respectively), hyperlipidemia (29.2%, 22.1%, and 49.6%), and endocrine

56 Of the 524 109 individuals with hyperlipidemia, 316 182 (60%) had >/=1 outpatient prescr

57 this cross-sectional study, 94 patients with hyperlipidemia (50 receiving statins and 44 receiving no

58 , hypertension (47.1% vs 45.4%; P = .73), or hyperlipidemia (52.3% vs 63.4%; P = .45).

59 ange, 53-71], 87% men, 85% hypertension, 51% hyperlipidemia, 56% smokers).

60 y, was less than 10%, with the exceptions of hyperlipidemia (6.1% vs 11.2%), hypertension (9.8% vs 18

61 rted rates of medication discontinuation for hyperlipidemia (60.7% vs 43.2%, P < .001), diabetes (ins

62 the most prevalent risk factor for NAION was hyperlipidemia (62.9%); for diabetic patients, NAION ris

63 an 90% of patients; agreement was lowest for hyperlipidemia (68%; kappa = 0.36) and arthritis (66%; k

64 pe 2 diabetes (22.51%; 95% CI: 17.92-27.89), hyperlipidemia (69.16%; 95% CI: 49.91-83.46%), hypertens

65 hypertension; 5) coronary heart disease; 6) hyperlipidemia; 7) alcohol abuse; 8) tobacco use disorde

66 risk factors included hypertension (83.3%), hyperlipidemia (83.3%), and small cup-to-disc ratio (63.

67 levels and displayed prolonged postprandial hyperlipidemia accompanied by increased granulocyte numb

68 We stratified patients with hyperlipidemia according to the risk categories outlined

69 zin-induced diabetic mice, hyperglycemia and hyperlipidemia acted reciprocally, accentuating renal in

70 d liver accumulation of glycogen and develop hyperlipidemia, adiposity as well as insulin resistance

71 e inhibited lesion formation and ameliorated hyperlipidemia after vascular injury and during atherosc

72 drome components (diabetes mellitus [DM] and hyperlipidemia; aHR, 1.44; CI, 1.12-1.84; P = 0.005) had

73 her with previous reports demonstrating that hyperlipidemia also impairs lung innate defense, these r

74 e younger and female but less likely to have hyperlipidemia, although other cardiovascular risk facto

75 ins) are widely prescribed for patients with hyperlipidemia and are generally well tolerated.

76 It is highly upregulated in hyperlipidemia and atherosclerosis in a CX3CR1-independe

77 expression of microRNA-30c (miR-30c) reduced hyperlipidemia and atherosclerosis in mice without causi

78 ther a miR-30c mimic can be used to mitigate hyperlipidemia and atherosclerosis without inducing stea

79 prevents the development of hyperglycaemia, hyperlipidemia and atherosclerosis.

80 of hepatic miR-30c by anti-miR-30c increased hyperlipidemia and atherosclerosis.

81 ge- and sex-matched groups: 18 patients with hyperlipidemia and CP (HLp), 18 periodontally healthy pa

82 itions such as coronary heart disease (CHD), hyperlipidemia and diabetes mellitus (DM).

83 besity-associated metabolic disorders (e.g., hyperlipidemia and diabetes) and periodontitis has been

84 ic Ces1/Ces1g in Apoe (-/-) mice resulted in hyperlipidemia and exacerbated Western diet-induced athe

85 to have diabetes mellitus, hypertension, and hyperlipidemia and have higher discharge blood pressures

86 ked HFD-induced obesity, insulin resistance, hyperlipidemia and hepatic steatosis.

87 diovascular risk but with a low frequency of hyperlipidemia and high intake of n-3 (omega-3) fatty ac

88 been associated with metabolic toxicities of hyperlipidemia and hyperglycemia.

89 ies such as fatty liver, insulin resistance, hyperlipidemia and hyperinsulinemia.

90 estimated national control of hyperglycemia, hyperlipidemia and hypertension (especially for young me

91 bid cardiovascular disease risk factors like hyperlipidemia and hypertension in low- and middle-incom

92 with diabetes had controlled hyperglycemia, hyperlipidemia and hypertension, respectively.

93 In this respect, although obesity promotes hyperlipidemia and hypothalamic injury, MC4R agonists ar

94 His medical history was significant for hyperlipidemia and hypothyroidism.

95 ed atherosclerosis through the generation of hyperlipidemia and increased adiposity.

96 ry-low density lipoproteins), which leads to hyperlipidemia and increased fat deposition in periphera

97 Increased lipogenesis, together with hyperlipidemia and increased fat deposition, contribute

98 peroxidation, accumulating in circulation in hyperlipidemia and inducing platelet activation by promo

99 muscle insulin resistance in aging promotes hyperlipidemia and NAFLD by altering the pattern of post

100 rapeutic strategies, especially for treating hyperlipidemia and obesity, and other drugs are in devel

101 s IL-6 expression, is upregulated by LPS and hyperlipidemia and patients with familial hypercholester

102 harmful oxidative status in association with hyperlipidemia and periodontitis.

103 reas the available therapy primarily targets hyperlipidemia and prevention of thrombosis.

104 cells might serve as a possible link between hyperlipidemia and psoriasis.

105 ly hypermethylated in Mvarphis isolated from hyperlipidemia and T2DM ischemic muscles compared with c

106 lammatory, proangiogenic M2-Mvarphi genes in hyperlipidemia and T2DM ischemic muscles.

107 nflammatory and proangiogenic M2-Mvarphis in hyperlipidemia and T2DM ischemic muscles.

108 Compared with the controls, hyperlipidemia and T2DM mice showed impaired perfusion r

109 s the periodontal status among patients with hyperlipidemia and users of statins.

110 g miR-30c levels might be useful in treating hyperlipidemias and associated disorders.

111 pathways linking diet-induced changes (e.g., hyperlipidemia) and the ensuing inflammation have remain

112 , hypertension, metabolic syndrome, smoking, hyperlipidemia, and a sedentary lifestyle are the major

113 and selected effects on glucose regulation, hyperlipidemia, and adipose pathology; but may not be as

114 a (PLA2g2a) is associated with inflammation, hyperlipidemia, and atherogenesis.

115 nd leader in the field of diabetes, obesity, hyperlipidemia, and atherosclerosis.

116 nd leader in the field of diabetes, obesity, hyperlipidemia, and atherosclerosis.

117 Insulin resistance, hyperlipidemia, and cardiovascular complications are com

118 r risk factors, including diabetes mellitus, hyperlipidemia, and cigarette smoking to cases.

119 rior to conception caused maternal and fetal hyperlipidemia, and consequently larger fetuses.

120 , geographic region, hypertension, diabetes, hyperlipidemia, and coronary heart disease, the hazard r

121 28% to 31% of US patients with hypertension, hyperlipidemia, and diabetes, may be improved by electro

122 barrier and is associated with proteinuria, hyperlipidemia, and edema.

123 mice develop severe lipodystrophy, diabetes, hyperlipidemia, and fatty liver disease within the first

124 ate lipogenesis, resulting in hyperglycemia, hyperlipidemia, and hepatic steatosis.

125 Diabetes, hyperlipidemia, and hypertension are modifiable risk fac

126 e achieved through modification of diabetes, hyperlipidemia, and hypertension by summarizing current

127 de advanced age, smoking, diabetes mellitus, hyperlipidemia, and hypertension.

128 carcinoma, comorbidity index, hypertension, hyperlipidemia, and obesity by Cox's proportional hazard

129 Diabetes, hypertension, hyperlipidemia, and obesity were all found to be risk fa

130 Charlson comorbidity scores, history of CVA, hyperlipidemia, and other cerebrovascular diseases.

131 rs (such as smoking, diabetes, hypertension, hyperlipidemia, and overweight) and encouraging healthy

132 bidity present among hypertension, diabetes, hyperlipidemia, and smoking (OR, 2.13, 95% CI, 1.51-2.99

133 Increased duration of ART, hyperlipidemia, and smoking contributed to proximal RCA

134 emographics, cohort, hypertension, diabetes, hyperlipidemia, and tobacco use, risk differences compar

135 etermine whether simvastatin consumption and hyperlipidemia are associated with a worse periodontal c

136 Oxidative stress, inflammation, and hyperlipidemia are common factors involved in the pathop

137 ive to the general population, patients with hyperlipidemia are more prone to periodontal disease.

138 ane biophysical changes due to infection and hyperlipidemia are one of the key mechanisms by which C.

139 Serum hyperlipidemias are common human diseases that could be

140 ls were determined to be sensitive to plasma hyperlipidemia, as evidenced by its approximately 3-fold

141 tory of smoking, hypertension, diabetes, and hyperlipidemia, as well as personal and family history o

142 on of miR-155-5p expression in beta-cells by hyperlipidemia-associated endotoxemia improves the adapt

143 In this study, we demonstrate that hyperlipidemia-associated endotoxemia upregulates miR-15

144 mine the role of CD1-autoreactive T cells in hyperlipidemia-associated inflammatory diseases.

145 rotein (MTP) inhibitors is limited to severe hyperlipidemias because of associated hepatosteatosis an

146 hronic diseases (diabetes, hypertension, and hyperlipidemia) between 2011 and 2013.

147 hronic diseases (diabetes, hypertension, and hyperlipidemia) between 2011 and 2013.

148 ase for diagnoses of NIDDM, hypertension, or hyperlipidemia; body mass index (BMI); lipid profile; an

149 ession was induced in response to injury and hyperlipidemia but was absent at later time points, and

150 She had no history of hyperlipidemia, but multiple blood samples were grossly

151 Hyperlipidemia, but not hyperglycemia, led to increased

152 ertension, cardiac conditions, diabetes, and hyperlipidemia, but not with whether patients had receiv

153 R-24 promotes hepatic lipid accumulation and hyperlipidemia by repressing Insig1, and suggest the use

154 nd the prothrombotic state in the setting of hyperlipidemia by sensing a wide range of endogenous lip

155 /- 6 [standard deviation]) with asymptomatic hyperlipidemia by using a 320-detector row scanner (Aqui

156 s the role of cafeteria diet-induced obesity/hyperlipidemia (CAF) on alveolar bone loss (ABL) in rats

157 ups: control, periodontitis (PERIO), obesity/hyperlipidemia (CAF), and obesity/hyperlipidemia plus pe

158 ss proteinuria, hypoalbuminaemia, edema, and hyperlipidemia, can be clinically divided into steroid-s

159 mmation of presence/absence of hypertension, hyperlipidemia, cardiac arrhythmias, coronary artery dis

160 e diabetes [prediabetes or type 2 diabetes], hyperlipidemia, cardiovascular events, and chronic kidne

161 For hyperlipidemia (cholesterol <200 mg/dL, high-density lip

162 ble analyses adjusting for Elixhauser index, hyperlipidemia, confounding drugs, and surgery type, odd

163 Obesity, diabetes, hypertension, and hyperlipidemia constitute risk factors for morbidity and

164 contributes to the development of diabetes, hyperlipidemia, coronary artery disease, and cancer.

165 Among patients with history of hyperlipidemia, countries in the highest tertile of gros

166 pendent of age, sex, diabetes, hypertension, hyperlipidemia, current smoking, left anterior descendin

167 tory included prostate cancer, hypertension, hyperlipidemia, deep-vein thrombosis, and stroke.

168 Resident participation; hypertension and hyperlipidemia detection, treatment, and control; smokin

169 lipid deposition to accentuate diet-induced hyperlipidemia, diabetes, and obesity.

170 therapy, including measures of hypertension, hyperlipidemia, diabetes, bone disease, and hematologic

171 nd stroke mortality, including hypertension, hyperlipidemia, diabetes, coronary heart disease, and ce

172 At baseline, women had lower rates of hyperlipidemia, diabetes, smoking, and renal disease but

173 Many young adults with moderate hyperlipidemia do not meet statin treatment criteria und

174 increases hepatic triglyceride synthesis and hyperlipidemia due to increased fatty acid esterificatio

175 failure, diabetes, asthma, hypertension, or hyperlipidemia) during the first six years of the study.

176 tients with psoriasis (n=105), patients with hyperlipidemia eligible for statin therapy under Nationa

177 Hyperlipidemia exacerbates ischemic stroke outcome and i

178 Elderly patients and those with hyperlipidemia experienced fewer typical symptoms than t

179 icantly elevated among adults with prolonged hyperlipidemia exposure by 55 years of age: 4.4% for tho

180 eridemias are diagnosed as familial combined hyperlipidemia (FCHL) and primary isolated hypertriglyce

181 rs (PPARs), has been generally used to treat hyperlipidemia for decades.

182 Hyperlipidemia found in CnAbeta(-/-) mice is, in part, d

183 es (hypertension, sleep apnea, diabetes, and hyperlipidemia), functional status, and patient satisfac

184 ions for 6 chronic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid

185 ween 8-OHdG and MDA was also observed in the hyperlipidemia group.

186 tributed to lipid levels change and incident hyperlipidemia >8.1-year follow-up among 6428 individual

187 ascular health, specifically the presence of hyperlipidemia, had a significant direct impact on ERC-t

188 we reveal that each rexinoid, which induced hyperlipidemia, had methyl groups that interacted with h

189 Hyperlipidemia has been extensively studied in the conte

190 ls with diabetes mellitus, hypertension, and hyperlipidemia have difficulty achieving control of all

191 ith better long-term %WL, while preoperative hyperlipidemia, higher body mass index, and older age we

192 HLp), 18 periodontally healthy patients with hyperlipidemia (HLh), 19 systemically healthy individual

193 the most common drugs for old patients with hyperlipidemia, hypercholesterolemia and atherosclerotic

194 diets, male LDLR(-/-) mice develop obesity, hyperlipidemia, hyperglycemia, and arteriosclerotic calc

195 Nod2 (-/-) HFD mice developed hyperlipidemia, hyperglycemia, glucose intolerance, incr

196 5 and HR = 2.70, 95% CI 1.81-4.03), although hyperlipidemia, hypertension, and COPD did not.

197 6-2011 evaluated MU in relation to diabetes, hyperlipidemia, hypertension, chronic obstructive pulmon

198 tory seem to be risk factors for MU, but not hyperlipidemia, hypertension, or COPD.

199 .5 g/24 h along with hypoalbuminemia, edema, hyperlipidemia (hypertriglyceridemia and hypercholestero

200 in the liver leads to hepatic steatosis and hyperlipidemia in animals under prolonged fasting.

201 I) guidelines on screening and management of hyperlipidemia in children and to discuss the critics co

202 anced perspective for screening and managing hyperlipidemia in children.

203 (-/-) dams developed glucose intolerance and hyperlipidemia in late pregnancy.

204 The molecular link between proteinuria and hyperlipidemia in nephrotic syndrome is not known.

205 ased use of medications for hypertension and hyperlipidemia in patients with no gap coverage and gene

206 y identify the influence of hyperglycemia or hyperlipidemia in producing specific cellular changes, s

207 but only the 7-methyl-9cUAB30 caused severe hyperlipidemia in rats.

208 Hepatic overexpression of miR-30c reduced hyperlipidemia in Western diet-fed mice by decreasing li

209 t association between cumulative exposure to hyperlipidemia in young adulthood and subsequent CHD ris

210 Cumulative exposure to hyperlipidemia in young adulthood increases the subseque

211 ted metabolic dysregulation characterized by hyperlipidemia, increased adiposity, and insulin resista

212 Atherosclerosis, a hyperlipidemia-induced chronic inflammatory process of t

213 inhibitors led to a significant decrease in hyperlipidemia-induced IL-1beta and IL-18 production, lo

214 lar diseases, presumably via amelioration of hyperlipidemia-induced monocytosis, and can be augmented

215 ased serum cholesterol levels and subsequent hyperlipidemia-induced monocytosis.

216 Such diets lead to obesity, hyperlipidemia, insulin resistance, and steatosis that m

217 Hyperlipidemia is a major risk factor for cardiovascular

218 Atherosclerosis, for which hyperlipidemia is a major risk factor, is the leading ca

219 Hyperlipidemia is a risk factor for various cardiovascul

220 Hyperlipidemia is frequent in DM2 patients, but the trea

221 systemic inflammatory state of patients with hyperlipidemia is indicated by their increased erythrocy

222 f miR-155-5p in the islet stress response to hyperlipidemia is unclear.

223 aired in diabetes and suggests that treating hyperlipidemia is vital for proper cardiac signaling and

224 Elevated plasma lipid content, or hyperlipidemia, is a significant risk factor for cardiov

225 history of hypertension, diabetes mellitus, hyperlipidemia, ischemic heart disease, stroke, total ch

226 ulin and adiponectin, severe lipoatrophy and hyperlipidemia lead to lethality.

227 gement of comorbidities such as diabetes and hyperlipidemia may help to limit late vascular complicat

228 Among obesity and hyperlipidemia measures no factors were related to perio

229 This review describes mechanisms underlying hyperlipidemia-mediated neutrophilia and how neutrophils

230 score, inherited aortopathies, hypertension, hyperlipidemia, medications, aortic regurgitation, and r

231 Obesity and hyperlipidemia modulate the host response to challenges

232 groups: 1) simvastatin-treated patients with hyperlipidemia (n = 29); 2) patients with hyperlipidemia

233 g antihypertensive medications), and 60% had hyperlipidemia, nearly half of whom were receiving lipid

234 the association between duration of moderate hyperlipidemia (non-high-density lipoprotein cholesterol

235 etabolic diseases including atherosclerosis, hyperlipidemia, obesity, and diabetes.

236 o lower lipid absorption in order to control hyperlipidemia, obesity, metabolic syndrome, steatosis,

237 es, including sex, statin use, hypertension, hyperlipidemia, obesity, self-reported race, smoking, an

238 cells in the human body under conditions of hyperlipidemia/obesity, OA-treated cells gain or reduce

239 duce lipoprotein particles, exacerbating the hyperlipidemia of fasting and postprandial states.

240 Preoperative hyperlipidemia, older age, and higher body mass index we

241 DM2 patients and controls with patients with hyperlipidemia on statin therapy.

242 of VI, obesity, hypertension, diabetes, and hyperlipidemia on the EQ-5D index score using linear reg

243 nt improvement in the prediction of incident hyperlipidemia on top of traditional risk factors includ

244 ion (P = .023), hypertension (P = .021), and hyperlipidemia or obesity (P = .0004) were more common i

245 sis showed diabetes mellitus (P = .0001) and hyperlipidemia or obesity (P = .0142) were more common i

246 ues from donors either with diabetes or with hyperlipidemia or obesity reduced the failure rate from

247 donors either with diabetes mellitus or with hyperlipidemia or obesity reduced the failure rate.

248 especially with longer disease duration) and hyperlipidemia or obesity were associated with higher fa

249 4.0% +/- 3.4%) with no significant impact of hyperlipidemia or smoking.

250 0; 95% confidence interval [CI], 1.28-5.27), hyperlipidemia (OR, 3.42; 95% CI, 1.55-7.56), and curren

251 Obesity (odds ratio [OR]: 2.13), hyperlipidemia (OR, 4.13), hypertension (OR, 3.67), high

252 nd CVD risk factors (diabetes, hypertension, hyperlipidemia) or subclinical CVD measures (coronary ar

253 a known diagnosis of hypertension, diabetes, hyperlipidemia, or CVD.

254 y in adults without known CVD, hypertension, hyperlipidemia, or diabetes.

255 x, education level, oral hygiene habits, and hyperlipidemia (P = 0.049).

256 demia than in the diet-treated patients with hyperlipidemia (P = 0.05).

257 nificant strongest associations for incident hyperlipidemia (P range from 1.20x10(-3) to 4.67x10(-16)

258 at lower traditional risk than patients with hyperlipidemia, patients with psoriasis had increased NC

259 ), obesity/hyperlipidemia (CAF), and obesity/hyperlipidemia plus periodontitis (CAF+PERIO).

260 New data suggest that diet, hyperlipidemia, pollutants, commensal microbes, and path

261 coronary artery disease, diabetes type 2 and hyperlipidemia presented with no symptoms of mitral valv

262 coronary artery disease, diabetes type 2 and hyperlipidemia presented with vertigo, headaches, mainly

263 models of atherosclerosis, normalization of hyperlipidemia promotes macrophage emigration and regres

264 be two novel immunodeficient mouse models of hyperlipidemia (Rag1(-/)(-)/LDLR(-/)(-) and Rag1(-/)(-)/

265 exhibited apparent phenotypes of obesity and hyperlipidemia regardless of exposure to casein injectio

266 reases over time and the incidence of future hyperlipidemia remains largely unknown.

267 pertension, coronary heart disease, obesity, hyperlipidemia, renal disease, hypothyroidism, and the n

268 The approach to management of hyperlipidemia should take two forms.

269 ients, the simvastatin-treated patients with hyperlipidemia showed a mean reduction of 0.8 mm (95% co

270 The presence of obesity and hyperlipidemia significantly increased ABL in the CAF+PE

271 s (obesity, diabetes mellitus, hypertension, hyperlipidemia, smoking) with >/=1 risk factors in 58% o

272 users (n = 1,272; 33.9%) had higher rates of hyperlipidemia, smoking, a history of percutaneous coron

273 ents' glycated hemoglobin A1c, hypertension, hyperlipidemia, smoking, and renal impairment.

274 ion exists that controls for factors such as hyperlipidemia, smoking, medication, and disease stage,

275 glucagon and T3 actions synergize to correct hyperlipidemia, steatohepatitis, atherosclerosis, glucos

276 This study demonstrates that oxLDL and hyperlipidemia stimulate the generation of NOX2-derived

277 a mouse model of combined hyperglycemia and hyperlipidemia (streptozotocin-induced diabetic apolipop

278 ensates for the antiproliferative effects of hyperlipidemia, such that atherosclerosis was exacerbate

279 her in the simvastatin-treated patients with hyperlipidemia than in the diet-treated patients with hy

280 was higher in the diet-treated patients with hyperlipidemia than in the normolipidemic controls (P =

281 including diuretics, blood lead levels, and hyperlipidemia, the odds ratios of gout and hyperuricemi

282 nate immunity in endothelium synergizes with hyperlipidemia to cause topographical distribution of at

283 the activated form of SREBP2 synergized with hyperlipidemia to increase atherosclerosis in the athero

284 groups, including populations without marked hyperlipidemia (total cholesterol level <200 mg/dL); abs

285 th hyperlipidemia (n = 29); 2) patients with hyperlipidemia treated by diet alone (n = 28); and 3) no

286 may provide a novel strategy for obesity and hyperlipidemia treatment.

287 creening of persons with a family history of hyperlipidemia vs. general screening) in younger adults.

288 tory of diabetes mellitus, hypertension, and hyperlipidemia was associated with greater intima-media

289 Midlife hypertension and hyperlipidemia were associated with 29% (prevalence rati

290 lacks only, whereas midlife hypertension and hyperlipidemia were associated with late-life ICAD in bo

291 triglyceride transfer activity might reduce hyperlipidemia while protecting liver from excess lipid

292 Individuals with hyperlipidemia who took statins continuously for 2 years

293 I were significantly higher in patients with hyperlipidemia who were non-statin users compared with t

294 lowering trials enrolling 4300 patients with hyperlipidemia who were randomly assigned to receive 150

295 However, whereas hyperlipidemia will enhance renal immune complex-mediate

296 s for devising novel strategies to attenuate hyperlipidemia, with the potential for cardiovascular di

297 nonalcoholic fatty liver disease (NAFLD) and hyperlipidemia, with their associated risks of endstage

298 n patients with coronary artery diseases and hyperlipidemia without effect on LDL level.

299 In mice, induction of hyperlipidemia worsened diaphragmatic oxidative stress d

300 Overall, 85% of young adults with prolonged hyperlipidemia would not have been recommended for stati